stock price decline

Class action lawsuit filed against $STLA for alleged misstatements on electrification prospects. February 2026 €22.2B reset triggered 23% stock decline; lead plaintiffs sought.

Pomerantz Law Firm launches investigation into $EHC following New York Times report of below-average hospital safety measures. Stock plummets 10.35%.

Immutep stock collapsed 82% after Phase III trial failure. Law firm investigates potential securities fraud regarding disclosure timing and adequacy.

Pomerantz Law Firm investigates Weis Markets securities fraud claims following February 2026 disclosure of overstated inventory requiring multi-year financial restatement, triggering 7.16% stock decline.

Disc Medicine stock tumbled 30% after FDA rejected bitopertin drug application, prompting securities fraud investigation by Pomerantz LLP.

Law firm Robbins Geller files class action against Driven Brands for alleged securities violations involving financial statement errors. Stock plummeted 40% after February 2026 disclosure.

Pomerantz Law Firm files class action against NuScale Power over undisclosed $495M payment to ENTRA1 Energy, causing 20% stock decline and $532M quarterly loss.

Pomerantz Law Firm filed class action against $QURE after 49% stock decline following FDA concerns over gene therapy study data adequacy.

Pomerantz Law Firm filed a class action lawsuit against $ODD, alleging executives concealed algorithmic changes by major ad partner that spiked customer acquisition costs and triggered 49% stock collapse.

Pomerantz LLP files class action against Inovio Pharmaceuticals for securities fraud over false FDA claims; stock fell 24.45% in December 2025.

Pomerantz LLP sues Nektar Therapeutics for alleged securities fraud over failed clinical trial enrollment; stock falls 7.77%.

Kyndryl Holdings faces 55% stock collapse after SEC financial reporting investigation and executive departures. Class action lawsuit filed; deadline April 13, 2026.

Law firm Faruqi & Faruqi investigates Medpace for alleged securities fraud over misleading backlog statements. Stock plunged 15.9% after disappointing guidance, with June 8, 2026 deadline for lead plaintiff claims.

Law firm Levi & Korsinsky files class action against Medpace Holdings over alleged false statements about backlog cancellations. Stock fell 15.9% after disappointing Q4 guidance.

Alight faces class-action lawsuit over alleged false revenue statements. Stock crashed 56%+ after two major earnings misses in 2025-2026.

Three Super Micro executives indicted for allegedly diverting $2.5B in AI servers to China. Stock crashed 33.3% on March 20, 2026. Class action lawsuit filed over undisclosed violations.

$NAVN shares crashed from $25 IPO to $9.20 following undisclosed $95M expense spike and CFO departure, triggering securities fraud lawsuit.

Law firm investigates Newegg after 17.7% stock decline following disclosure that chairman He Zhitao was detained for personal legal issues.

GSI Technology shares fell 14.2% after allegations its AI chip cannot run Gemma-3 workloads. Rosen Law Firm launched securities investigation for potential class action.

Class action lawsuit filed against Inovio Pharmaceuticals for allegedly making false statements about manufacturing deficiencies and overstating regulatory prospects, triggering 24.45% stock decline.